Company profile
MATINAS BIOPHARMA HOLDINGS, INC.
AMEX:MTNBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OMEGA-3-PENTAENOIC ACIDS | phase3 | — | 2 | completed, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02310022 | phase1_2 | completed | 2014-11-01 | 2015-05-01 | Matinas Biopharma, Inc | A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules |
| NCT02629419 | phase2 | completed | 2016-09-27 | 2021-11-09 | Matinas BioPharma Nanotechnologies, Inc. | CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis |
| NCT03167957 | phase2 | withdrawn | 2019-12-01 | 2020-12-01 | Matinas BioPharma Nanotechnologies, Inc. | Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis |
| NCT03196921 | phase1_2 | withdrawn | 2018-10-01 | 2019-10-01 | Matinas BioPharma Nanotechnologies, Inc. | Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection |
| NCT04031833 | phase1_2 | completed | 2019-10-24 | 2022-11-14 | Matinas BioPharma Nanotechnologies, Inc. | Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) |
FDA applications (0)
No records yet.